As documented in large randomized controlled trials (RCTs), the administration of either antithrombin III or human recombinant thrombomodulin could improve short-term mortality among septic patients, but no trails specifically targeted patients with postoperative sepsis (34, 35). Here, THBD is linked to Sepsis.